Avidity Biosciences (RNA) Competitors $41.44 +1.22 (+3.03%) Closing price 04:00 PM EasternExtended Trading$41.50 +0.06 (+0.14%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RNA vs. TEVA, SMMT, GMAB, ASND, VTRS, RDY, QGEN, BBIO, MRNA, and VRNAShould you be buying Avidity Biosciences stock or one of its competitors? The main competitors of Avidity Biosciences include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Ascendis Pharma A/S (ASND), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), QIAGEN (QGEN), BridgeBio Pharma (BBIO), Moderna (MRNA), and Verona Pharma PLC American Depositary Share (VRNA). These companies are all part of the "pharmaceutical products" industry. Avidity Biosciences vs. Its Competitors Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Ascendis Pharma A/S Viatris Dr. Reddy's Laboratories QIAGEN BridgeBio Pharma Moderna Verona Pharma PLC American Depositary Share Teva Pharmaceutical Industries (NYSE:TEVA) and Avidity Biosciences (NASDAQ:RNA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, earnings, profitability and analyst recommendations. Which has higher valuation and earnings, TEVA or RNA? Avidity Biosciences has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Avidity Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.30-$1.64B-$0.16-116.81Avidity Biosciences$10.90M489.11-$322.30M-$3.56-11.64 Which has more volatility and risk, TEVA or RNA? Teva Pharmaceutical Industries has a beta of 0.72, suggesting that its share price is 28% less volatile than the S&P 500. Comparatively, Avidity Biosciences has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Do insiders & institutionals believe in TEVA or RNA? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 3.8% of Avidity Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is TEVA or RNA more profitable? Teva Pharmaceutical Industries has a net margin of -0.95% compared to Avidity Biosciences' net margin of -4,247.77%. Teva Pharmaceutical Industries' return on equity of 46.10% beat Avidity Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-0.95% 46.10% 7.18% Avidity Biosciences -4,247.77%-33.45%-30.22% Do analysts rate TEVA or RNA? Teva Pharmaceutical Industries currently has a consensus target price of $24.71, suggesting a potential upside of 32.23%. Avidity Biosciences has a consensus target price of $68.94, suggesting a potential upside of 66.37%. Given Avidity Biosciences' higher probable upside, analysts plainly believe Avidity Biosciences is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25Avidity Biosciences 0 Sell rating(s) 0 Hold rating(s) 17 Buy rating(s) 1 Strong Buy rating(s) 3.06 Does the media prefer TEVA or RNA? In the previous week, Avidity Biosciences had 19 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 33 mentions for Avidity Biosciences and 14 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 1.05 beat Avidity Biosciences' score of 0.68 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 9 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Avidity Biosciences 12 Very Positive mention(s) 5 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryTeva Pharmaceutical Industries beats Avidity Biosciences on 9 of the 17 factors compared between the two stocks. Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RNA vs. The Competition Export to ExcelMetricAvidity BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.17B$3.12B$5.73B$10.31BDividend YieldN/A2.36%5.90%4.63%P/E Ratio-11.6421.1675.8626.51Price / Sales489.11446.35528.74123.58Price / CashN/A45.4037.1760.46Price / Book3.479.6212.796.29Net Income-$322.30M-$53.28M$3.28B$270.51M7 Day Performance-11.11%0.31%0.22%2.15%1 Month Performance-10.82%4.58%4.61%6.35%1 Year Performance-0.74%9.24%68.33%25.48% Avidity Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RNAAvidity Biosciences2.0792 of 5 stars$41.44+3.0%$68.94+66.4%-3.6%$5.17B$10.90M-11.64190Analyst ForecastTEVATeva Pharmaceutical Industries2.7152 of 5 stars$19.30+1.8%$24.71+28.1%+2.7%$21.73B$16.54B-120.6136,830SMMTSummit Therapeutics3.3707 of 5 stars$19.44-25.2%$33.79+73.8%-40.7%$19.30BN/A-19.25110Positive NewsAnalyst ForecastHigh Trading VolumeGMABGenmab A/S3.9323 of 5 stars$27.54flat$37.60+36.5%+4.1%$17.67B$3.12B13.842,682Positive NewsASNDAscendis Pharma A/S2.9466 of 5 stars$205.22-0.3%$244.36+19.1%+63.2%$12.60B$393.54M-39.771,017Positive NewsVTRSViatris1.6033 of 5 stars$10.48-0.2%$10.40-0.8%-17.7%$12.24B$14.74B-3.6132,000RDYDr. Reddy's Laboratories2.4264 of 5 stars$14.27-0.5%$16.95+18.8%-9.0%$11.97B$3.81B21.6127,811Positive NewsQGENQIAGEN4.4124 of 5 stars$47.62+0.1%$49.69+4.4%+0.7%$10.57B$1.98B28.135,765Positive NewsBBIOBridgeBio Pharma4.4139 of 5 stars$54.29+1.7%$63.35+16.7%+96.6%$10.20B$221.90M-13.27400Analyst ForecastMRNAModerna4.5233 of 5 stars$24.83-1.2%$42.88+72.7%-65.0%$9.78B$3.24B-3.305,800News CoverageVRNAVerona Pharma PLC American Depositary Share2.2925 of 5 stars$106.300.0%$109.00+2.5%+257.2%$9.20B$42.28M-107.3730Positive News Related Companies and Tools Related Companies Teva Pharmaceutical Industries Competitors Summit Therapeutics Competitors Genmab A/S Competitors Ascendis Pharma A/S Competitors Viatris Competitors Dr. Reddy's Laboratories Competitors QIAGEN Competitors BridgeBio Pharma Competitors Moderna Competitors Verona Pharma PLC American Depositary Share Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RNA) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredOpenAI’s new $300 billion dealOpenAI just signed a $300 billion cloud deal with Oracle to secure the computing power needed for its next Cha...Porter & Company | SponsoredNew Buy Alert: Should you put $1,000 into Oracle (ORCL) now?Barron's is calling this Oracle's "Nvidia Moment..." While the Wall Street Journal is simply calling Oracle...Chaikin Analytics | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RNA Stock Alerts